Literature DB >> 14505860

Primary malignant lymphoma of the trigeminal region treated with rapid infusion of high-dose MTX and radiation: case report and review of the literature.

Manabu Kinoshita1, Shuichi Izumoto, Satoru Oshino, Masahiro Nonaka, Shusuke Moriuchi, Motohiko Maruno, Toshiki Yoshimine.   

Abstract

BACKGROUND: Extra-axial primary CNS lymphoma, considered rare, mainly arise in the white matter of the brain. Though the tumor responds well to radiation and chemotherapy, the prognosis of primary CNS lymphoma remains poor. We report a case of primary lymphoma of Meckel's cave mimicking a trigeminal schwannoma radiographically, which achieved complete remission through use of rapid high-dose MTX therapy and radiation therapy. CASE DESCRIPTION: The patient, a 55-year-old Japanese male, presented left trigeminal neuralgia. Magnetic resonance imaging (MRI) revealed a mass lesion in the left side of Meckel's cave, with extension into the cerebellopontine angle and the infratemporal fossa through the foramen ovale, suggesting trigeminal schwannoma. However, the patient suffered radiologically inexplicable progressive cranial nerve palsy, which suggested malignant disease. MRI and CSF disclosed malignant tumor dissemination; biopsy revealed malignant lymphoma. The treatment, composed of the rapid infusion of high-dose MTX and whole brain and spine radiation, resulted in complete remission.
CONCLUSIONS: This case, which included atypical presentation of malignant lymphoma, illustrates the importance of including malignant lymphoma in the differential diagnosis of CP-angle and Meckel's cave tumor. The results also confirmed the usefulness of combined rapid high-dose MTX therapy and radiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14505860     DOI: 10.1016/s0090-3019(02)01046-7

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  8 in total

1.  Infraorbital nerve swelling associated with autoimmune pancreatitis.

Authors:  Tomoharu Watanabe; Yasunari Fujinaga; Satoshi Kawakami; Tomoko Hatta; Hideaki Hamano; Shigeyuki Kawa; Masumi Kadoya
Journal:  Jpn J Radiol       Date:  2011-04-26       Impact factor: 2.374

2.  Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.

Authors:  Sigal Grisariu; Batia Avni; Tracy T Batchelor; Martin J van den Bent; Felix Bokstein; David Schiff; Outi Kuittinen; Marc C Chamberlain; Patrick Roth; Anatoly Nemets; Edna Shalom; Dina Ben-Yehuda; Tali Siegal
Journal:  Blood       Date:  2010-04-05       Impact factor: 22.113

3.  Malignant lymphoma of the trigeminal region. Case illustration.

Authors:  Ketan R Bulsara; Paulo A Kadri; Muhammad Husain; Ossama Al-Mefty
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

4.  Central nervous system lymphoma presenting as trigeminal neuralgia: A diagnostic challenge.

Authors:  Jensen W J Ang; Arjun Khanna; Brian P Walcott; Kristopher T Kahle; Emad N Eskandar
Journal:  J Clin Neurosci       Date:  2015-04-10       Impact factor: 1.961

5.  P001. Trigeminal neuralgia-like symptoms: an unusual case.

Authors:  Andrea Giorgetti; Patrizia Perrone; Maria V Calloni; Serena Leva; Francesco Muscia; Lucia Politini; Emilio Vecchio
Journal:  J Headache Pain       Date:  2015-12       Impact factor: 7.277

6.  Diffuse large B cell lymphoma involving Meckel's cave masquerading as biopsy-negative giant cell arteritis: a case report.

Authors:  Matthew J Samec; Andres G Madrigal; Charlotte H Rydberg; Matthew J Koster
Journal:  J Med Case Rep       Date:  2020-05-10

7.  Long-term survival of diffuse large B cell lymphoma of the trigeminal region extending to the Meckel's cave treated by CHASER therapy: case report.

Authors:  Toshihide Tanaka; Naoki Kato; Kuniaki Itoh; Yuzuru Hasegawa
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-12-05       Impact factor: 1.742

Review 8.  Access to Meckel's cave for biopsies of indeterminate lesions: a systematic review.

Authors:  E Suero Molina; J M Revuelta Barbero; C Ewelt; W Stummer; R L Carrau; D M Prevedello
Journal:  Neurosurg Rev       Date:  2020-02-10       Impact factor: 3.042

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.